Oramed appoints Yehuda Reznick as director and audit committee chair effective April 1, 2024

ORAMED PHARMACEUTICALS INC.

Yehuda Reznick appointed to fill existing board vacancy; also audit committee chair and designated financial expert.
Reznick, 76, was an audit partner at Kesselman & Kesselman (PwC affiliate) from 1999 to 2014.
Compensation same as other non-executive directors; standard indemnification agreement expected.
Currently serves on board of Oravax Medical Inc., an affiliate of Oramed.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Yehuda Reznick

director

ORMP · ORAMED PHARMACEUTICALS INC.

Effective: 2024-04-01
Filed: March 18, 2024, 7:59 PM ET

On March 12, 2024, Oramed Pharmaceuticals Inc. (the “Company”) appointed Mr. Yehuda Reznick to serve as a director, effective as of April 1, 2024, to fill an existing vacancy on the board of directors (the “Board”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Yehuda Reznick was appointed as director at ORAMED PHARMACEUTICALS INC..

Action: appointed
Role: director

Exact text from the filing

On March 12, 2024, Oramed Pharmaceuticals Inc. (the “Company”) appointed Mr. Yehuda Reznick to serve as a director, effective as of April 1, 2024, to fill an existing vacancy on the board of directors (the “Board”).

View on SEC.gov

ORAMED PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001213900-24-023584

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.